Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2017; 9(01): 036-041
DOI: 10.4103/0974-2727.187925
Original Article

Urine Albumin Excretion as a Marker of Acute Glycemic Changes in Isolated Postprandial Hyperglycemia

Alagilawada S Shilpasree
Department of Biochemistry, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
,
Vidya S Patil
Department of Biochemistry, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
,
Vijayetha P Patil
Department of Biochemistry, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
,
Deepti G Ingleshwar
Department of Biochemistry, SDM College of Medical Sciences and Hospital, Dharwad, Karnataka, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

Introduction: Postprandial hyperglycemia is a major risk factor for the development of cardiovascular diseases (CVDs), and Most of the times it occurs in patients with normal glycemic control diagnosed by fasting blood glucose (FBG) and glycated hemoglobin levels. Urine albumin excretion (UAE) is an independent predictor of CVD risk.

Aim: To estimate UAE in isolated postprandial hyperglycemia (IPPHG) patients and to assess the relationship of UAE with FBG and postprandial blood glucose (PPBG) levels.

Settings and Design: A cross-sectional study was carried out in 318 patients with Type II diabetes in the age group 30–60 years for 6 months.

Materials and Methods: Patients were divided into five groups based on their FBG and PPBG values. UAE and lipid profile were measured in all the groups.

Statistical Analysis: UAE and lipid profile in different groups were compared using ANOVA. Regression analysis was used to predict the variation of UAE with FBG, PPBG, and total cholesterol (TC).

Results: Patients with IPPHG had significantly higher albumin excretion compared to normoglycemia (NG) group [P < 0.0001]. In impaired glucose tolerance and isolated fasting hyperglycemia groups, it did not differ significantly from NG group [P = 0.206 and P = 0.173]. Lipid profile did not show any significant difference between the groups. On regression analysis, PPBG but not FBG or TC correlated positively with UAE.

Conclusion: UAE is easy, less expensive, and Widely available method done on spot urine samples which predicts the acute glycemic changes and increased risk of developing CVDs in patients with IPPHG.

Key words

Hyperglycemia - impaired glucose tolerance - normoglycemia - urine albumin excretion


Publication History

Article published online:
19 February 2020

© 2017.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
  • 2 American Diabetes Association. Standards of medical care in diabetes ߝ 2014. Diabetes Care 2014;37 Suppl 1:S14-80.
  • 3 Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005;54:1-7.
  • 4 Suzuki H, Fukushima M, Usami M, Ikeda M, Taniguchi A, Nakai Y, et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 2003;26:1211-5.
  • 5 Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in Type 2 diabetes: Implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-9.
  • 6 Chinenye S, Young EE. Isolated postprandial hyperglycemia in Type 2 diabetic patients in a Nigerian Tertiary Health Center. Indian J Endocrinol Metab 2012;16:604-8.
  • 7 Wajchenberg BL. Postprandial glycemia and cardiovascular disease in diabetes mellitus. Arq Bras Endocrinol Metabol 2007;51:212-21.
  • 8 Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009;8:23.
  • 9 Pollak J, Sypniewska G. Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension. Biochem Med 2008;18:25-34.
  • 10 Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol 2006;17:2106-11.
  • 11 Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: The EPIC-Norfolk study. Am J Epidemiol 2004;159:284-93.
  • 12 Pradeepa R, Mohan V. Postprandial glycaemic excursions and cardiovascular risk. J Indian Med Assoc 2011;109:912, 917-20.
  • 13 Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up. Diabetologia 1996;39:1577-83.
  • 14 DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
  • 15 Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000;35:898-903.
  • 16 Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in Type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-65.
  • 17 Strain WD, Chaturvedi N, Bulpitt CJ, Rajkumar C, Shore AC. Albumin excretion rate and cardiovascular risk: Could the association be explained by early microvascular dysfunction? Diabetes 2005;54:1816-22.
  • 18 Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
  • 19 Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension: A marker, treatment target, or innocent bystander? Diabetes Care 2008;31 Suppl 2:S194-201.
  • 20 Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16.
  • 21 de Castro SH, Castro-Faria-Neto HC, Gomes MB. Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetes ߝ a cross-sectional study. Rev Diabet Stud 2005;2:157-64.
  • 22 Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 1999;48:1503-8.
  • 23 Ge QM, Dong Y, Zhang HM, Su Q. Effects of intermittent high glucose on oxidative stress in endothelial cells. Acta Diabetol 2010;47 Suppl 1:97-103.
  • 24 Saab C, Issa C, Zantout MS, Azar ST. Contributions of overnight glycemia to the overall hyperglycemia of type 2 diabetic patients: Variations with HbA1c levels. J Diabetes Sci Technol 2014;8:619-20.
  • 25 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA (1c). Diabetes Care 2003;26:881-5.
  • 26 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
  • 27 Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-9.
  • 28 Singh SK. Post-prandial hyperglycemia. Indian J Endocrinol Metab 2012;16 Suppl 2:S245-7.
  • 29 Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: Should we care? Diabetes Care 2011;34 Suppl 2:S120-7.